V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210002661 | 210010151 | 1.58 | 0 | Adjuvant (A) | null | 2018-01-30 | Docetaxel | 02 | N | DOCETAXEL | 101653172 |
| 210002662 | 210010152 | 1.72 | 88.8 | null | 2018-09-05 | 2018-12-28 | EC | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101694590 |
| 210002663 | 210010153 | 1.59 | 85.7 | null | 2018-07-04 | 2019-01-01 | EC | 2 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100836789 |
| 210002669 | 210010154 | 1.62 | 56 | Neo-adjuvant (N) | null | 2019-03-31 | Trastuzumab | null | N | TRASTUZUMAB | 101746297 |
| 210002672 | 210010157 | 1.59 | 60.6 | Adjuvant (A) | null | 2018-10-22 | Docetaxel | 02 | N | DOCETAXEL | 101420735 |
| 210002674 | 210010158 | 1.45 | 83.4 | Palliative (P) | 2021-07-05 | 2021-09-08 | Docetaxel | 02 | null | DOCETAXEL | 101657779 |
| 210002676 | 210010160 | 1.65 | 94.7 | Adjuvant (A) | null | 2021-07-29 | EC | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101080226 |
| 210002683 | 210010162 | 1.58 | 73.7 | Adjuvant (A) | 2022-03-22 | 2022-05-25 | Docetaxel 75mg/m2 (21 day) | 02 | N | DOCETAXEL | 100272511 |
| 210002688 | 210010164 | 1.69 | 91.7 | Neo-adjuvant (N) | 2020-01-17 | 2020-02-01 | Trastuzumab | 02 | N | TRASTUZUMAB | 100802577 |
| 210002689 | 210010165 | 1.54 | 88.3 | Adjuvant (A) | 2020-05-24 | 2020-08-24 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101447983 |
| 210002690 | 210010166 | 1.65 | 65.2 | Adjuvant (A) | 2018-01-08 | 2019-05-05 | EC | 02 | Y | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101000028 |
| 210002695 | 210010168 | null | 43 | null | null | 2020-05-07 | Docetaxel | 02 | null | DOCETAXEL | 100147319 |
| 210002696 | 210010169 | 1.64 | 78.9 | Adjuvant (A) | null | 2019-05-04 | TRASTUZUMAB | 02 | N | TRASTUZUMAB | 100348719 |
| 210002697 | 210010170 | 0 | 77.5 | null | 2017-11-18 | 2018-01-29 | Docetaxel | 02 | null | DOCETAXEL | 101293716 |
| 210002701 | 210010172 | 1.75 | 83.6 | Adjuvant (A) | 2018-10-25 | 2018-11-09 | Trastuzumab Subcutaneous | 02 | null | TRASTUZUMAB | 100082008 |
| 210002709 | 210010175 | 1.69 | 91 | Adjuvant (A) | null | 2020-12-26 | Docetaxel 100mg/m2 (21 day) | null | N | DOCETAXEL | 100935404 |
| 210002713 | 210010177 | null | 91 | Adjuvant (A) | null | 2017-12-13 | Docetaxel | 02 | N | DOCETAXEL | 100963064 |
| 210002714 | 210010178 | null | 80 | null | null | 2019-10-18 | Docetaxel | 02 | null | DOCETAXEL | 101309372 |
| 210002716 | 210010179 | 1.63 | 76.5 | Adjuvant (A) | null | 2016-09-02 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 101582032 |
| 210002717 | 210010180 | 1.56 | 97.7 | Neo-adjuvant (N) | null | 2020-09-03 | Trastuzumab Subcutaneous | null | null | TRASTUZUMAB | 101177175 |
| 210002719 | 210010182 | 1.44 | 76.4 | Neo-adjuvant (N) | 2021-11-05 | 2022-01-09 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100224117 |
| 210002725 | 210010184 | null | 84.3 | null | null | 2020-12-10 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100897893 |
| 210002727 | 210010186 | 1.67 | 58 | Adjuvant (A) | 2020-10-13 | 2020-12-02 | TRASTUZUMAB | 2 | N | TRASTUZUMAB | 101352147 |
| 210002728 | 210010187 | 1.71 | 71.4 | Palliative (P) | 2016-06-29 | 2016-09-20 | PACLITAXEL | 02 | N | PACLITAXEL | 101046182 |
| 210002729 | 210010188 | null | 84.3 | Palliative (P) | 2022-03-20 | 2022-04-18 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100087721 |
| 210002731 | 210010190 | 1.5 | 71.1 | null | 2020-03-19 | 2020-06-13 | Docetaxel 75mg/m2 (21 day) | N | null | DOCETAXEL | 100380953 |
| 210002736 | 210010192 | null | 88 | Disease modification (D) | null | 2017-02-27 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101364491 |
| 210002737 | 210010193 | 1.67 | 78.4 | null | 2018-07-12 | 2018-11-02 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100852551 |
| 210002744 | 210010195 | 1.71 | 75.1 | Adjuvant (A) | null | 2017-11-17 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100919723 |
| 210002745 | 210010196 | 1.76 | 49.2 | Palliative (P) | 2020-05-24 | 2020-08-16 | Docetaxel | null | N | DOCETAXEL | 101607927 |
| 210002746 | 210010197 | 1.56 | 88.9 | Adjuvant (A) | null | 2017-08-28 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101764552 |
| 210002748 | 210010198 | 1.57 | null | Adjuvant (A) | 2016-04-20 | 2016-06-29 | Docetaxel 100mg/m2 (21 day) | 02 | N | DOCETAXEL | 100649391 |
| 210002750 | 210010199 | 1.69 | 63.6 | Palliative (P) | 2021-01-20 | 2021-02-08 | Docetaxel | null | null | DOCETAXEL | 101359563 |
| 210002751 | 210010200 | 1.56 | 78.3 | Neo-adjuvant (N) | null | 2017-01-28 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100755182 |
| 210002754 | 210010202 | 1.54 | 68.6 | Adjuvant (A) | 2017-12-11 | 2017-12-13 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101343732 |
| 210002755 | 210010203 | 1.63 | 86.4 | Adjuvant (A) | 2022-04-04 | 2022-05-24 | Trastuzumab | 01 | N | TRASTUZUMAB | 100776013 |
| 210002756 | 210010204 | 1.7 | 88.5 | Adjuvant (A) | 2020-07-17 | 2020-07-25 | EC | N | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100142963 |
| 210002757 | 210010205 | 1.67 | 50.4 | null | null | 2016-09-20 | Docetaxel 100mg/m2 (21 day) | null | N | DOCETAXEL | 101755554 |
| 210002760 | 210010207 | 1.78 | 68.2 | Adjuvant (A) | 2020-04-27 | 2020-06-05 | PACLITAXEL | null | N | PACLITAXEL | 101454782 |
| 210002761 | 210010208 | 1.66 | 59.8 | null | null | 2017-03-02 | PACLITAXEL | null | null | PACLITAXEL | 100837925 |
| 210002764 | 210010209 | 1.58 | 70.2 | null | null | 2019-05-20 | Docetaxel | null | N | DOCETAXEL | 100270661 |
| 210002767 | 210010212 | 1.56 | 100 | Adjuvant (A) | 2019-11-11 | 2020-05-22 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 101856601 |
| 210002768 | 210010213 | 1.61 | 60 | Adjuvant (A) | null | 2017-05-17 | PACLITAXEL | N | null | PACLITAXEL | 100461865 |
| 210002773 | 210010214 | 1.62 | 110 | Neo-adjuvant (N) | 2017-02-19 | 2017-09-21 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100097853 |
| 210002774 | 210010215 | 1.59 | null | Neo-adjuvant (N) | null | 2022-03-10 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100800687 |
| 210002777 | 210010217 | 1.54 | 99.2 | null | 2020-07-02 | 2020-07-10 | Trastuzumab | 01 | null | TRASTUZUMAB | 100476756 |
| 210002779 | 210010218 | 1.7 | 66 | Adjuvant (A) | 2020-05-12 | 2020-06-16 | Paclitaxel 7 day | 02 | N | PACLITAXEL | 100559144 |
| 210002781 | 210010219 | 1.61 | 57 | Adjuvant (A) | 2019-10-17 | 2019-12-20 | EC | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100515355 |
| 210002782 | 210010220 | 1.74 | 49 | Palliative (P) | 2020-05-03 | 2020-07-17 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100046605 |
| 210002783 | 210010221 | 1.58 | 95 | Neo-adjuvant (N) | 2017-01-31 | 2017-02-08 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 101475663 |